Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L.

AAPS J. 2017 Jul;19(4):1123-1135. doi: 10.1208/s12248-017-0083-7. Epub 2017 Apr 24.

PMID:
28439809
2.

Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.

Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SC, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O'Donnell CJ, Subramanyam C.

ACS Med Chem Lett. 2016 Jun 22;7(11):977-982. eCollection 2016 Nov 10.

3.

Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.

Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC.

Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18.

4.

Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice.

Kasaian MT, Page KM, Fish S, Brennan A, Cook TA, Moreira K, Zhang M, Jesson M, Marquette K, Agostinelli R, Lee J, Williams CM, Tchistiakova L, Thakker P.

Immunology. 2014 Nov;143(3):416-27. doi: 10.1111/imm.12319.

5.

Activation of TrkB with TAM-163 results in opposite effects on body weight in rodents and non-human primates.

Perreault M, Feng G, Will S, Gareski T, Kubasiak D, Marquette K, Vugmeyster Y, Unger TJ, Jones J, Qadri A, Hahm S, Sun Y, Rohde CM, Zwijnenberg R, Paulsen J, Gimeno RE.

PLoS One. 2013 May 20;8(5):e62616. doi: 10.1371/journal.pone.0062616. Print 2013.

6.

An IL-4/IL-13 dual antagonist reduces lung inflammation, airway hyperresponsiveness, and IgE production in mice.

Kasaian MT, Marquette K, Fish S, DeClercq C, Agostinelli R, Cook TA, Brennan A, Lee J, Fitz L, Brooks J, Vugmeyster Y, Williams CM, Lofquist A, Tchistiakova L.

Am J Respir Cell Mol Biol. 2013 Jul;49(1):37-46. doi: 10.1165/rcmb.2012-0500OC.

PMID:
23449738
7.

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP.

Mol Cancer Ther. 2013 Jan;12(1):38-47. doi: 10.1158/1535-7163.MCT-12-0603. Epub 2012 Dec 5.

8.

IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.

Kasaian MT, Raible D, Marquette K, Cook TA, Zhou S, Tan XY, Tchistiakova L.

J Immunol. 2011 Jul 1;187(1):561-9. doi: 10.4049/jimmunol.1100467. Epub 2011 May 27.

9.

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells.

Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, DiJoseph JF, Karnoub M, Huang S, Diesl V, Behrens C, Choe SE, Rios C, Gruzas J, Sridharan L, Dougher M, Kunz A, Hamann PR, Evans D, Armellino D, Khandke K, Marquette K, Tchistiakova L, Boghaert ER, Abraham RT, Wistuba II, Zhou BB.

Cancer Res. 2011 Jun 15;71(12):4236-46. doi: 10.1158/0008-5472.CAN-10-3919. Epub 2011 May 3.

10.

Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys.

Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, Cook TA, Lee J, Widom A, Agostinelli R, Bree A, Schlerman FJ, Olland S, Wadanoli M, Sypek J, Gill D, Goldman SJ, Tchistiakova L.

J Pharmacol Exp Ther. 2008 Jun;325(3):882-92. doi: 10.1124/jpet.108.136515. Epub 2008 Mar 12.

PMID:
18337474
11.

The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.

Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, Harrop R, Kunz A, Hamann PR, Marquette K, Dougher M, DiJoseph JF, Damle NK.

Int J Oncol. 2008 Jan;32(1):221-34.

PMID:
18097562
12.

IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys.

Bree A, Schlerman FJ, Wadanoli M, Tchistiakova L, Marquette K, Tan XY, Jacobson BA, Widom A, Cook TA, Wood N, Vunnum S, Krykbaev R, Xu X, Donaldson DD, Goldman SJ, Sypek J, Kasaian MT.

J Allergy Clin Immunol. 2007 May;119(5):1251-7. Epub 2007 Mar 26.

PMID:
17379289
13.

Efficacy of IL-13 neutralization in a sheep model of experimental asthma.

Kasaian MT, Donaldson DD, Tchistiakova L, Marquette K, Tan XY, Ahmed A, Jacobson BA, Widom A, Cook TA, Xu X, Barry AB, Goldman SJ, Abraham WM.

Am J Respir Cell Mol Biol. 2007 Mar;36(3):368-76. Epub 2006 Oct 5.

PMID:
17023688
14.

Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation.

Tsuchihashi S, Fondevila C, Shaw GD, Lorenz M, Marquette K, Benard S, Shen XD, Ke B, Busuttil RW, Kupiec-Weglinski JW.

J Immunol. 2006 Jan 1;176(1):616-24.

15.

Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, Collins M, Carreno BM.

J Immunol. 2003 Jan 15;170(2):711-8.

16.

The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand.

Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL.

J Clin Invest. 1997 Jun 1;99(11):2682-90.

17.

The factor V B-domain provides two functions to facilitate thrombin cleavage and release of the light chain.

Marquette KA, Pittman DD, Kaufman RJ.

Blood. 1995 Oct 15;86(8):3026-34.

PMID:
7579396
18.

A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells.

Marquette KA, Pittman DD, Kaufman RJ.

J Biol Chem. 1995 Apr 28;270(17):10297-303.

19.

Role of the B domain for factor VIII and factor V expression and function.

Pittman DD, Marquette KA, Kaufman RJ.

Blood. 1994 Dec 15;84(12):4214-25.

PMID:
7994036
20.

A2 domain of human recombinant-derived factor VIII is required for procoagulant activity but not for thrombin cleavage.

Pittman DD, Millenson M, Marquette K, Bauer K, Kaufman RJ.

Blood. 1992 Jan 15;79(2):389-97.

PMID:
1730084
21.

Denaturing gradient gel electrophoresis identifies genomic DNA polymorphism with high frequency in maize.

Riedel GE, Swanberg SL, Kuranda KD, Marquette K, Lapan P, Bledsoe P, Kennedy A, Lin BY.

Theor Appl Genet. 1990 Jul;80(1):1-10. doi: 10.1007/BF00224008.

PMID:
24220803

Supplemental Content

Loading ...
Support Center